Share
Geoffrey M. Glass
Abzena, a leading end-to-end integrated CDMO + CRO specializing in complex biologics and bioconjugates, has appointed Geoffrey M. Glass as its new Chief Executive Officer (CEO).
Mr. Glass, who has served as Chairman of the Board since 2022, brings over 30 years of experience in the life sciences sector, spanning both innovative drug developers and service organizations.
With more than 15 years dedicated to advancing the CDMO industry, Mr. Glass has held senior leadership roles at EY Consulting, Valeant Pharmaceuticals (now Bausch Health), Patheon (now Thermo Fisher Scientific), Sancilio Pharmaceuticals, and KINICITI.
His appointment represents a significant milestone in Abzena’s ongoing growth strategy. As the company enhances its global capabilities and strengthens partnerships across the biopharma ecosystem, Mr. Glass’s leadership will be pivotal in driving Abzena’s mission to accelerate the development and delivery of breakthrough therapies to patients worldwide.
.jpg "GENFIT Appoints Dr. Pejvack Motlagh as Chief Medical Officer")
